Patient Case Presentation: 65-year-old woman with platinum-resistant ovarian cancer
Managing Ocular Side Effects of ADCs ADC therapy often leads to ocular side effects, requiring proactive management. A typical patient scenario involved mild vision issues that escalated to moderate keratopathy. Regular ophthalmologic monitoring and timely intervention allowed continuation of treatment at a reduced dose while maintaining visual function. Standard care includes a baseline eye exam, ongoing optometry visits, steroid and lubricating drops, and close coordination between oncology and eye care. Dose holds and reductions based on severity are effective in reversing toxicity while maintaining disease control. This case illustrates that with proper planning, patients can stay on effective therapy despite complications. Collaborative care between oncologists and eye specialists ensures that ocular side effects are addressed early, allowing treatment continuity and preserving quality of life.
EP: 1.Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
EP: 2.The Role of Molecular Testing in Ovarian Cancer Care
EP: 3.From Challenges to Solutions: Ensuring Timely and Effective Molecular Testing in Ovarian Cancer
EP: 4.Mirvetuximab Soravtansine in Ovarian Cancer: Clinical Perspectives and Key Insights from MIRASOL
EP: 5.Advances in ADC Therapy for Ovarian Cancer
EP: 6.Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
EP: 7.Patient Case Presentation: 65-year-old woman with platinum-resistant ovarian cancer
Managing Ocular Side Effects of ADCs
ADC therapy often leads to ocular side effects, requiring proactive management. A typical patient scenario involved mild vision issues that escalated to moderate keratopathy. Regular ophthalmologic monitoring and timely intervention allowed continuation of treatment at a reduced dose while maintaining visual function.
Standard care includes a baseline eye exam, ongoing optometry visits, steroid and lubricating drops, and close coordination between oncology and eye care. Dose holds and reductions based on severity are effective in reversing toxicity while maintaining disease control.
This case illustrates that with proper planning, patients can stay on effective therapy despite complications. Collaborative care between oncologists and eye specialists ensures that ocular side effects are addressed early, allowing treatment continuity and preserving quality of life.
